[{"orgOrder":0,"company":"Nanjing Nutrabuilding Bio-tech Co., Ltd.","sponsor":"Biofortis M\u00e9rieux Nutriscience","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Dihydroberberine","moa":"AMPK pathway|mitochondrial complex I","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nanjing Nutrabuilding Bio-tech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nanjing Nutrabuilding Bio-tech Co., Ltd. \/ Biofortis M\u00e9rieux Nutriscience","highestDevelopmentStatusID":"1","companyTruncated":"Nanjing Nutrabuilding Bio-tech Co., Ltd. \/ Biofortis M\u00e9rieux Nutriscience"}]

Find Clinical Drug Pipeline Developments & Deals for Dihydroberberine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Nanjing Nutrabuilding Bio-tech Co., Ltd.

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Nanjing Nutrabuilding Bio-tech Co., Ltd.

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Dihydroberberine is a small molecule drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Prediabetic State.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 07, 2025

                          Lead Product(s) : Dihydroberberine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Sponsor : Biofortis Mérieux Nutriscience

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank